19:45 , Jul 5, 2017 |  BC Week In Review  |  Clinical News

DSMC recommends continuation of Biotron's Phase II trial of BIT225 for HIV-1 infection

Biotron Ltd. (ASX:BIT) said an independent DSMC recommended continuation of the Phase II BIT225-009 trial of BIT225 to treat HIV-1 infection based on safety data from the first cohort of 9 patients. The trial will...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

BIT225: Additional Phase II data

Additional data from treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all patients with HCV genotype 3 infection who received twice-daily...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

BIT225: Interim Phase II data

Interim data from 12 treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all 6 patients with HCV genotype 3 infection who...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

BIT225: Completed Phase II enrollment

In July, Biotron completed enrollment of 12 treatment-naïve patients co-infected with HIV and HCV genotype 1, 2 or 3 in an open-label, Thai Phase II trial evaluating 300 mg BIT225 once daily on days 7...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

BIT225: Preliminary Phase Ib/IIa data

Biotron said preliminary data from a Thai Phase Ib/IIa trial in 21 treatment-naïve patients with HIV infection showed that twice-daily 400 mg BIT225 for 10 days is capable of significantly reducing HIV RNA levels in...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

BIT225: Phase II started

Biotron began an open-label, Thai Phase II trial to evaluate 300 mg BIT225 once daily on days 7 and 35 and twice daily on days 8-34 in combination with pegylated interferon alfa-2b and ribavirin starting...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Clinical News

BIT225: Additional Phase IIa data

Additional data from a double-blind, Thai Phase IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that twice-daily oral BIT225 for 28 days plus standard of care (SOC; peginterferon alfa-2b and ribavirin)...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

BIT225: Preliminary Phase IIa data

Preliminary data from a double-blind, Thai Phase IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that 200 and 400 mg oral BIT225 for 28 days plus standard of care (SOC; peginterferon...
07:00 , Oct 17, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Insmed Inc. (NASDAQ:INSM) fell $1.34 (31%) to $3.01 on Monday after FDA told the company it is maintaining a clinical hold on a planned Phase III trial of Arikace in cystic fibrosis patients with Pseudomonas...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

BIT225: Phase II ongoing

Biotron began enrollment of a second set of 12 patients in a double-blind, placebo-controlled, Thai Phase II trial to evaluate 200 or 400 mg BIT225 in combination with Pegasys peginterferon alfa-2a and Copegus...